Arcus Biosciences RCUS Cash and cash equivalents, end of period
Cash and cash equivalents, end of period at other companies
Other financials
Where this comes from
Reported directly by Arcus Biosciences in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations.
The official record: Arcus Biosciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Arcus Biosciences's cash and cash equivalents, end of period.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Arcus Biosciences's cash and cash equivalents, end of period?
- Arcus Biosciences (RCUS) reported cash and cash equivalents, end of period of $204M in Q1 2026.
- How has Arcus Biosciences's cash and cash equivalents, end of period changed year-over-year?
- Arcus Biosciences's cash and cash equivalents, end of period increased by 4.6% year-over-year, from $195M to $204M.
- What is the long-term trend for Arcus Biosciences's cash and cash equivalents, end of period?
- Over 4 years (2021 to 2025), Arcus Biosciences's cash and cash equivalents, end of period has grown at a 10.5% compound annual growth rate (CAGR), from $151M to $225M.